ancer [J]. Cancer, 1997,80(5):892-895.
[4] HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN J, et al. p53 mutations in human cancers[J]. Science, 1991,49(3):253-256.
[5] 尤 宗兵,郭燕燕,曹泽毅. 野生型p53 基因转染对卵巢细胞系SKOV-3 生物学行为的影响[J].中华妇产科杂志,1997,32(7):715-717.
[6] RIGHETTI S C, DELLA T G, PILOTTI S, et al. A compar-ative study of p53 gene mutation protein accumulation and re-sponse to cisplatin based chemotherapy in advanced ovarian carcinoma [J]. Cancer Res, 1995,5(12):1345-1348.
[7] LEVINE A J, MOMAND J, FINLAY A. The p53 tumor sup-pressor gene [J]. Nature (Lond), 1991,351:452-456.
[8] VANMEIR E G, POLVERNI P J, CHAZIN V R, et al. Re-lease of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cell[J]. Nat Genet, 1994,8:171-176.
[9] 孙 衍增,牛兆山. P53蛋白和增殖细胞核抗原在前列腺癌中的表达及意义[J].青岛大学医学院学报,2001,37(4):309-311.
上一页 [1] [2] [3]